$CRIS
CURIS INC Stock $cris

$cris Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-Q Financial Statement

#000110820520000016 Filed on November 10, 2020

Income Statement

Concept	2020 Q4	2020 Q3	2019 Q4
Revenue	$3.024M	$2.742M	$3.287M
YoY Change	-8.0%	-3.99%	19.31%
Cost Of Revenue	$150.0K	$140.0K	$160.0K
YoY Change	-6.25%	-6.67%	6.67%
Gross Profit	$2.870M	$2.610M	$3.130M
YoY Change	-8.31%	-3.69%	19.92%
Gross Profit Margin	94.91%	95.19%	95.22%
Selling, General & Admin	$3.540M	$2.610M	$3.000M
YoY Change	18.0%	-9.69%	-1.32%
% of Gross Profit	123.34%	100.0%	95.85%
Research & Development	$5.610M	$4.705M	$7.460M
YoY Change	-24.8%	-8.59%	58.39%
% of Gross Profit	195.47%	180.27%	238.34%
Depreciation & Amortization	$20.00K	$60.00K	$30.00K
YoY Change	-33.33%	100.0%	-25.0%
% of Gross Profit	0.7%	2.3%	0.96%
Operating Expenses	$9.150M	$4.705M	$10.46M
YoY Change	-12.52%	-8.59%	34.97%
Operating Profit	-$6.275M	-$4.711M	-$7.334M
YoY Change	-14.44%	-11.5%	42.46%
Interest Expense	$10.00K	$0.00	$100.0K
YoY Change	-90.0%		-112.66%
% of Operating Profit
Other Income/Expense, Net	-$1.250M	-$1.263M	-$1.380M
YoY Change	-9.42%	13.48%
Pretax Income	-$7.520M	-$5.970M	-$8.610M
YoY Change	-12.66%	-7.3%	44.95%
Income Tax
% Of Pretax Income
Net Earnings	-$7.517M	-$5.974M	-$8.609M
YoY Change	-12.68%	-7.18%	44.91%
Net Earnings / Revenue	-248.58%	-217.87%	-261.91%
Basic Earnings Per Share		-$0.11
Diluted Earnings Per Share	-$113.9K	-$0.11	-$259.3K
COMMON SHARES
Basic Shares Outstanding	58.82M shares	54.55M shares	33.20M shares
Diluted Shares Outstanding		54.55M shares

Balance Sheet

Concept	2020 Q4	2020 Q3	2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$168.5M	$23.60M	$20.50M
YoY Change	721.95%	-15.71%	-15.64%
Cash & Equivalents	$129.6M	$23.60M	$15.43M
Short-Term Investments	$38.90M	$0.00	$5.100M
Other Short-Term Assets	$1.200M	$2.000M	$1.300M
YoY Change	-7.69%	11.11%	62.5%
Inventory
Prepaid Expenses
Receivables	$3.043M	$2.744M	$3.244M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$172.8M	$28.30M	$25.00M
YoY Change	590.93%	-13.4%	-10.58%
LONG-TERM ASSETS
Property, Plant & Equipment	$663.0K	$696.0K	$154.0K
YoY Change	330.52%	242.86%	-42.32%
Goodwill	$9.000M	$8.982M	$9.000M
YoY Change	0.0%	0.0%	0.2%
Intangibles
YoY Change
Long-Term Investments	$14.60M
YoY Change
Other Assets	$3.000K	$3.000K	$3.000K
YoY Change	0.0%	0.0%	50.0%
Total Long-Term Assets	$31.61M	$17.41M	$10.10M
YoY Change	212.81%	82.11%	7.44%
TOTAL ASSETS
Total Short-Term Assets	$172.8M	$28.30M	$25.00M
Total Long-Term Assets	$31.61M	$17.41M	$10.10M
Total Assets	$204.4M	$45.71M	$35.11M
YoY Change	482.1%	8.21%	-6.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.166M	$4.323M	$4.465M
YoY Change	-6.7%	74.46%	53.49%
Accrued Expenses	$3.625M	$2.736M	$1.910M
YoY Change	89.79%	49.43%	-44.75%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$557.0K	$222.0K	$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$10.08M	$9.123M	$6.541M
YoY Change	54.09%	93.37%	-50.63%
LONG-TERM LIABILITIES
Long-Term Debt	$334.0K	$668.0K	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$334.0K	$64.50M	$0.00
YoY Change			-100.0%
Total Long-Term Liabilities	$668.0K	$668.0K	$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.08M	$9.123M	$6.541M
Total Long-Term Liabilities	$668.0K	$668.0K	$0.00
Total Liabilities	$73.69M	$74.32M	$69.02M
YoY Change	6.77%	8.88%	64.87%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.047B	-$1.000B	-$1.017B
YoY Change	2.94%	0.0%	3.26%
Common Stock	$1.178B	$1.011B	$983.1M
YoY Change	19.78%	2.89%	0.28%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$130.7M	-$28.61M	-$33.91M
YoY Change
Total Liabilities & Shareholders Equity	$204.4M	$45.71M	$35.11M
YoY Change	482.1%	8.21%	-6.04%

Cashflow Statement

Concept	2020 Q4	2020 Q3	2019 Q4
OPERATING ACTIVITIES
Net Income	-$7.517M	-$5.974M	-$8.609M
YoY Change	-12.68%	-7.18%	44.91%
Depreciation, Depletion And Amortization	$20.00K	$60.00K	$30.00K
YoY Change	-33.33%	100.0%	-25.0%
Cash From Operating Activities	-$5.720M	-$5.870M	-$5.600M
YoY Change	2.14%	-12.52%	13.36%
INVESTING ACTIVITIES
Capital Expenditures	-$20.00K	-$160.0K	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$53.45M	$0.00	$1.540M
YoY Change	-3570.78%	-100.0%	-66.88%
Cash From Investing Activities	-$53.47M	-$160.0K	$1.550M
YoY Change	-3549.68%	-111.03%	-66.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	165.2M	5.820M	-1.060M
YoY Change	-15687.74%	-1054.1%	-35.37%
NET CHANGE
Cash From Operating Activities	-5.720M	-5.870M	-5.600M
Cash From Investing Activities	-53.47M	-160.0K	1.550M
Cash From Financing Activities	165.2M	5.820M	-1.060M
Net Change In Cash	106.0M	-210.0K	-5.110M
YoY Change	-2175.15%	-96.42%	164.77%
FREE CASH FLOW
Cash From Operating Activities	-$5.720M	-$5.870M	-$5.600M
Capital Expenditures	-$20.00K	-$160.0K	$0.00
Free Cash Flow	-$5.700M	-$5.710M	-$5.600M
YoY Change	1.79%	-14.9%	13.36%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001108205
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2020-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-30347
	dei	Entity Registrant Name EntityRegistrantName	CURIS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3505116
	dei	Entity Address Address Line1 EntityAddressAddressLine1	128 Spring Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Building C - Suite 500
	dei	Entity Address City Or Town EntityAddressCityOrTown	Lexington
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02421
	dei	City Area Code CityAreaCode	617
	dei	Local Phone Number LocalPhoneNumber	503-6500
	dei	Security12b Title Security12bTitle	Common Stock, Par Value $0.01 per share
	dei	Trading Symbol TradingSymbol	CRIS
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2020Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	58817444	shares
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23555000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15430000	USD
CY2020Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	0	USD
CY2019Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	153000	USD
CY2020Q3	us-gaap	Restricted Investments Current RestrictedInvestmentsCurrent	0	USD
CY2019Q4	us-gaap	Restricted Investments Current RestrictedInvestmentsCurrent	5113000	USD
CY2020Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2744000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3244000	USD
CY2020Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2003000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1063000	USD
CY2020Q3	us-gaap	Assets Current AssetsCurrent	28302000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	25003000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	696000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	154000	USD
CY2020Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	816000	USD
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	816000	USD
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6915000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	149000	USD
CY2020Q3	us-gaap	Goodwill Goodwill	8982000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	8982000	USD
CY2020Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3000	USD
CY2020Q3	us-gaap	Assets Assets	45714000	USD
CY2019Q4	us-gaap	Assets Assets	35107000	USD
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	4323000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4465000	USD
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2736000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1910000	USD
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1842000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	166000	USD
CY2020Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	222000	USD
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	9123000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6541000	USD
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5194000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2020Q3	cris	Royalty Guarantees Commitments Amount Noncurrent RoyaltyGuaranteesCommitmentsAmountNoncurrent	59337000	USD
CY2019Q4	cris	Royalty Guarantees Commitments Amount Noncurrent RoyaltyGuaranteesCommitmentsAmountNoncurrent	62477000	USD
CY2020Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	668000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2020Q3	us-gaap	Liabilities Liabilities	74322000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	69018000	USD
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	151875000	shares
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	56652885	shares
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	56652885	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	101250000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33241793	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33241793	shares
CY2020Q3	us-gaap	Common Stock Value CommonStockValue	566000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	332000	USD
CY2020Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1010198000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	982738000	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1039372000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1016981000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	-28608000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-33911000	USD
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	45714000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35107000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2742000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2856000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7811000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6717000	USD
CY2020Q3	us-gaap	Royalty Expense RoyaltyExpense	135000	USD
CY2019Q3	us-gaap	Royalty Expense RoyaltyExpense	145000	USD
	us-gaap	Royalty Expense RoyaltyExpense	382000	USD
	us-gaap	Royalty Expense RoyaltyExpense	342000	USD
CY2020Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	4705000	USD
CY2019Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	5147000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	17459000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	14840000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2613000	USD
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2887000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8593000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8557000	USD
CY2020Q3	us-gaap	Costs And Expenses CostsAndExpenses	7453000	USD
CY2019Q3	us-gaap	Costs And Expenses CostsAndExpenses	8179000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	26434000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	23739000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4711000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5323000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18623000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17022000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	58000	USD
CY2020Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2019Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-3495000	USD
CY2020Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	3000	USD
CY2019Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	170000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	513000	USD
CY2020Q3	cris	Non Cash Imputed Interest Expense NonCashImputedInterestExpense	1266000	USD
CY2019Q3	cris	Non Cash Imputed Interest Expense NonCashImputedInterestExpense	1303000	USD
	cris	Non Cash Imputed Interest Expense NonCashImputedInterestExpense	3848000	USD
	cris	Non Cash Imputed Interest Expense NonCashImputedInterestExpense	2721000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	0	USD
CY2019Q3	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Expense InterestExpense	791000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	20000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	22000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-17000	USD
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1263000	USD
CY2019Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1113000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3768000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6511000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-5974000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-6436000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-22391000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-23533000	USD
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.19
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.52
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.71
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	54554129	shares
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	33202871	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42884201	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	33170844	shares
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-5974000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-6436000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-22391000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-23533000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	3000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	3000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5974000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6433000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22391000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23530000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-33911000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	625000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-9709000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	-40269000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	15965000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	585000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	29000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	18000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-6708000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	-30380000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	262000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	624000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-5974000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	-28608000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-4496000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	651000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-9884000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	-13729000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	631000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	42000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-7213000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	-20269000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	684000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	3000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-6436000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	-26018000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-22391000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-23533000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	116000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	97000	USD
	cris	Non Cash Lease Expense NonCashLeaseExpense	104000	USD
	cris	Non Cash Lease Expense NonCashLeaseExpense	-26000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1833000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1966000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	8000	USD
	cris	Non Cash Imputed Interest Expense Net Of Imputed Interest NonCashImputedInterestExpenseNetOfImputedInterest	35000	USD
	cris	Non Cash Imputed Interest Expense Net Of Imputed Interest NonCashImputedInterestExpenseNetOfImputedInterest	267000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-35000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	51000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-3495000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-8000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-500000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	33000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	940000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	798000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	684000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2006000	USD
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	2367000	USD
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	2927000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20024000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20606000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	10914000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	5078000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	4950000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	657000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	41000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4421000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6005000	USD
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	890000	USD
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	USD
	cris	Proceeds From Issuance Of Private Placement Net Of Issuance Costs ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts	17500000	USD
	cris	Proceeds From Issuance Of Private Placement Net Of Issuance Costs ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1535000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	cris	Proceeds From Royalty Purchase Agreement ProceedsFromRoyaltyPurchaseAgreement	0	USD
	cris	Proceeds From Royalty Purchase Agreement ProceedsFromRoyaltyPurchaseAgreement	65000000	USD
	cris	Paymentsof Issuance Costs On Royalty Interest Purchase Agreement PaymentsofIssuanceCostsOnRoyaltyInterestPurchaseAgreement	0	USD
	cris	Paymentsof Issuance Costs On Royalty Interest Purchase Agreement PaymentsofIssuanceCostsOnRoyaltyInterestPurchaseAgreement	584000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	47000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	42000	USD
	cris	Payments Of Future Royalty Liability Net Of Imputed Interest PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest	3175000	USD
	cris	Payments Of Future Royalty Liability Net Of Imputed Interest PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest	1139000	USD
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	0	USD
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	37162000	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	0	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	1825000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	23575000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	24332000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	7972000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2279000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16399000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23636000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24371000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21357000	USD
	us-gaap	Interest Paid Net InterestPaidNet	3824000	USD
	us-gaap	Interest Paid Net InterestPaidNet	2559000	USD
	cris	Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Shares Issued Value NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssuedValue	900000	USD
	cris	Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Shares Issued Value NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssuedValue	0	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	7029000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1046000	USD
	us-gaap	Nature Of Operations NatureOfOperations	Nature of Business<div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Curis, Inc. is a biotechnology company focused on the development of first-in-class and innovative therapeutics for the treatment of cancer. Throughout these Condensed Consolidated Financial Statements, Curis, Inc. and its wholly owned subsidiaries are collectively referred to as “the Company,” or “Curis.”</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin lymphomas, including those with Myeloid Differentiation Primary Response 88 alterations, and in a Phase 1 trial in patients with acute myeloid leukemia and myelodysplastic syndromes. The Company is also planning a combination study of CA-4948 and ibrutinib, a BTK inhibitor, in non-Hodgkin lymphomas In addition, in January 2020 Curis entered into a collaboration with ImmuNext Inc. (“ImmuNext”) for the development of CI-8993, a monoclonal antibody designed to antagonize the VISTA signaling pathway, which is currently undergoing testing in a Phase 1a/1b trial in patients with solid tumors. Curis is also party to a collaboration with Genentech Inc. (“Genentech”), a member of the Roche Group, under which Genentech and F. Hoffman-La Roche Ltd (“Roche”)are commercializing Erivedge</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of advanced basal cell carcinoma (“BCC”). In 2015, Curis entered into a collaboration with Discovery Technologies Limited (“Aurigene”) Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis exercised its option to license two orally available small molecule antagonists of immune checkpoints, the VISTA/PDL1 antagonist CA-170 and the TIM3/PDL1 antagonist CA-327, as well as the orally available small molecule IRAK4 inhibitor CA-4948, and a fourth program, which is an immuno-oncology program.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, an outbreak of respiratory illness caused by a strain of novel coronavirus, COVID-19, began in China. That outbreak has led to millions of confirmed cases worldwide, including in the Unites States and other countries where the Company is conducting clinical trials or activities in support thereof. The World Health Organization declared the outbreak a global public health emergency on January 30, 2020 and declared it a pandemic on March 11, 2020. In addition to those who have been directly affected, billions more have been affected by governmental efforts around the world to slow the spread of the outbreak. The outbreak and government measures taken in response have also had a significant impact, both direct and indirect, on businesses and commerce. The COVID-19 pandemic has had and may continue to have an adverse effect on the Company’s business, financial condition, results of operations, and prospects. With respect to ongoing clinical trials, the anticipated timing of enrollment, in addition to data collection and the overall timelines of the trials, have experienced delays and could be further delayed due to the extent the Company experiences further delays in enrollment due to the COVID-19 pandemic. The Company is also experiencing delays in closing down its clinical trial sites related to its fimepinostat and CA-170 trials due to restrictions on non-essential workers imposed at those sites in response to COVID-19, which has delayed the winding down of these trials and may result in additional costs and expenses. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its collaborators, third-party contract manufacturers, contract research organizations and clinical sites could experience delays or disruptions in supply and release of product candidates and/or procuring items that are essential for its research and development activities, including, for example, raw materials used in the manufacturing of its product candidates, basic medical and laboratory supplies used in its clinical trials or preclinical studies, or animals that are used for preclinical testing, in each case, for which there may be shortages because of ongoing efforts to address the outbreak. Some of the Company’s product candidates, or materials contained therein, may come from facilities located in areas impacted by COVID-19, including India, China, and Europe. In addition, any disruptions could impact the supply, manufacturing or distribution of Erivedge, and sales of Erivedge may be negatively impacted by a decrease in new prescriptions as a result of a decline in patient medical visits due to the COVID-19 pandemic, which could negatively impact the amount and timing of any royalty revenue the Company may receive from Genentech related to Erivedge. Additionally, the pandemic has already caused significant disruptions in the financial markets, and may continue to cause such disruptions, which could impact the Company’s ability to raise additional funds. The Company cannot be certain what the overall impact of the COVID-19 pandemic will be on its business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry as well as risks that are specific to the Company’s business, including, but not limited to: the Company’s ability to continue as a going concern; the Company’s ability to obtain adequate financing to fund its operations; the Company’s ability to advance and expand its research and development programs; the impacts of the COVID-19 pandemic and responsive actions related thereto; the Company’s relationship with Aurigene to support development of drug candidates under the parties’ collaboration agreement; the Company’s reliance on Roche and Genentech to successfully commercialize Erivedge in the approved indication of advanced BCC and to progress its clinical development in indications other than BCC; the ability of the Company and its wholly owned subsidiary, Curis Royalty, LLC (“Curis Royalty”) to satisfy the terms of the royalty interest purchase agreement (the “Oberland Purchase Agreement”) with TPC Investments I LP and TPC Investments II LP, (the “Purchasers”), each of which is a Delaware limited partnership managed by Oberland Capital Management, LLC, and Lind SA LLC, (the “Agent”), a Delaware limited </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liability company managed by Oberland Capital Management, LLC, as collateral agent for the Purchasers; the Company’s ability to obtain and maintain necessary intellectual property protection; development by the Company’s competitors of new or better technological innovations; the Company's dependence on key personnel; the Company’s ability to comply with regulatory requirements; the Company's ability to obtain and maintain applicable regulatory approvals and commercialize any approved product candidates: the Company’s ability to execute on its overall business strategies; and the Company’s ability to maintain its listing on the Nasdaq Global Stock Market.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s future operating results will largely depend on the progress of drug candidates currently in its development pipeline and the magnitude of payments that it may receive and make under its current and potential future collaborations. The results of the Company’s operations have varied and will likely continue to vary significantly from year to year and quarter to quarter and depend on a number of factors, including, but not limited to: the timing, outcome and cost of the Company’s preclinical studies and clinical trials for its drug candidates; Aurigene’s ability to support advancement of development candidates under the Company’s collaboration with Aurigene, as well as the Company’s ability to further develop programs under this collaboration; and Roche and Genentech’s ability to successfully commercialize Erivedge.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred net losses and negative cash flows from operations since its inception. As of September 30, 2020, the Company had an accumulated deficit of approximately $1.0 billion, and for the nine months ended September 30, 2020, the Company incurred a net loss of $22.4 million and used $20.0 million of cash in operations. The Company expects to continue to generate operating losses in the foreseeable future. The Company anticipates that its $23.6 million of existing cash and cash equivalents at September 30, 2020 should enable the Company to maintain its planned operations through the second quarter of 2021. Based on the Company's available cash resources, recurring losses and cash outflows from operations since inception, an expectation of continuing operating losses and cash outflows from operations for the foreseeable future and the need to raise additional capital to finance its future operations, the Company concluded it does not have sufficient cash on hand to support current operations within the next 12 months from the date of filing this Quarterly Report on Form 10-Q. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. The Company expects to finance its operations through its common stock purchase agreement with Aspire Capital Fund LLC (“Aspire Capital”), and its at-the-market sales agreement with JonesTrading Institutional Services LLC (“JonesTrading”), or other potential equity financings, debt financings or other capital sources. However, the Company may not be successful in securing additional financing on acceptable terms, or at all. Furthermore, high volatility in the capital markets resulting from the COVID-19 pandemic has had, and could continue to have, a negative impact on the price of the Company’s common stock, and could adversely impact the Company’s ability to raise additional funds. The Company’s ability to raise additional funds will depend, among other factors, on financial, economic and market conditions, many of which are outside of its control and it may be unable to raise financing when needed, or on terms favorable to the Company. If necessary funds are not available, the Company will have to delay, reduce the scope of, or eliminate some of its development programs, potentially delaying the time to market for or preventing the marketing of any of its product candidates.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in light of the Company’s limited cash resources, it may seek to engage in one or more strategic alternatives, such as a strategic partnership with one or more parties, the licensing, sale or divestiture of some of its assets or proprietary technologies or the sale of the Company, but there can be no assurance that the Company would be able to enter into such a transaction or transactions on a timely basis or on terms favorable to it, or at all.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CARES Act PPP Loan</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2020, the Company entered into a promissory note evidencing an unsecured $0.9 million loan (the “PPP Loan”) under the Paycheck Protection Program (“PPP”), of the Coronavirus Aid, Relief, and Economic Security Act, (“CARES Act”). The PPP Loan was made by Silicon Valley Bank (“SVB”). The term of the PPP Loan is 24-months. The interest rate on the PPP Loan is 1%, which shall be deferred for the first six months of the term of the loan. The promissory note evidencing the PPP Loan contains customary events of default relating to, among other things, payment defaults, breach of representations and warranties, or provisions of the promissory note, and cross-default provisions. The occurrence of an event of default may result in the repayment of all amounts outstanding, collection of all amounts the Company owes, and/or filing suit and obtaining judgment against the Company.</span></div>Under the terms of the CARES Act and the Paycheck Protection Program Flexibility Act of 2020, PPP Loan recipients can apply for and be granted forgiveness for all or a portion of loans granted under the PPP. Such forgiveness will be determined, subject to limitations, based on the use of loan proceeds for payroll costs and mortgage interest, rent or utility costs and the maintenance of employee and compensation levels. No assurance is provided that the Company will obtain forgiveness of the PPP Loan in whole or in part.
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1000000000.0	USD
	us-gaap	Net Income Loss NetIncomeLoss	-22400000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20000000.0	USD
CY2020Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	23600000	USD
	us-gaap	Use Of Estimates UseOfEstimates	The preparation of the Company’s Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosure of certain assets and liabilities at the balance sheet date. Such estimates include the performance obligations under the Company’s collaboration agreements; the estimated repayment term of the Company’s debt and related short- and long-term classification; the fair value of the Company’s debt; the collectability of receivables; the carrying value of property and equipment; and the assumptions used in the Company’s valuation of stock-based compensation and the value of certain investments and liabilities. Actual results may differ from such estimates.
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23600000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15400000	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21400000	USD
CY2020Q3	us-gaap	Restricted Cash RestrictedCash	800000	USD
CY2019Q4	us-gaap	Restricted Cash RestrictedCash	1000000.0	USD
CY2019Q3	us-gaap	Restricted Cash RestrictedCash	200000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24400000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21400000	USD
	cris	Available For Sale Securities Weighted Average Maturity AvailableForSaleSecuritiesWeightedAverageMaturity	P0Y1M6D
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	5113000	USD
CY2020Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	478000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	208000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	5113000	USD
CY2019	cris	Available For Sale Securities Weighted Average Maturity AvailableForSaleSecuritiesWeightedAverageMaturity	P0Y1M6D
CY2020Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	0	USD
CY2020Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1467000	USD
CY2019Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1413000	USD
CY2020Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	228000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	289000	USD
CY2020Q3	cris	Accrued License Fees Current AccruedLicenseFeesCurrent	563000	USD
CY2019Q4	cris	Accrued License Fees Current AccruedLicenseFeesCurrent	0	USD
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2736000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P6Y7M6D
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1910000	USD
CY2020Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	7000000.0	USD
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6900000	USD
CY2020Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y7M6D
CY2020Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0995
CY2020Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	400000	USD
CY2019Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	300000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	1000000.0	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	800000	USD
CY2020Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	0	USD
CY2019Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	300000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	200000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	800000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	272000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2421000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1144000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1178000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1213000	USD
CY2020Q3	cris	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	2971000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	9199000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2163000	USD
CY2020Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	7036000	USD
CY2019Q1	cris	Royalty Purchase Agreement Liability RoyaltyPurchaseAgreementLiability	65000000.0	USD
CY2019Q1	cris	Royalty Purchase Agreement Interest Rate RoyaltyPurchaseAgreementInterestRate	0.083
CY2019Q1	cris	Royalty Purchase Agreement Transaction Fees And Closing Costs RoyaltyPurchaseAgreementTransactionFeesAndClosingCosts	600000	USD
CY2019Q4	cris	Royalty Purchase Agreement Liability RoyaltyPurchaseAgreementLiability	62477000	USD
	cris	Royalty Purchase Agreement Issuance Costs Capitalized Amortization RoyaltyPurchaseAgreementIssuanceCostsCapitalizedAmortization	46000	USD
	cris	Royalty Purchase Agreement Accretion Expense RoyaltyPurchaseAgreementAccretionExpense	3802000	USD
	cris	Payments Of Future Royalty Liability PaymentsOfFutureRoyaltyLiability	6988000	USD
CY2020Q3	cris	Royalty Purchase Agreement Liability Carrying Value RoyaltyPurchaseAgreementLiabilityCarryingValue	59337000	USD
CY2019Q1	cris	Royalty Purchase Agreement Liability RoyaltyPurchaseAgreementLiability	65000000	USD
	cris	Royalty Purchase Agreement Issuance Costs Capitalized RoyaltyPurchaseAgreementIssuanceCostsCapitalized	584000	USD
	cris	Royalty Purchase Agreement Accretion Expense RoyaltyPurchaseAgreementAccretionExpense	4055000	USD
	cris	Payments Of Future Royalty Liability PaymentsOfFutureRoyaltyLiability	5994000	USD
CY2019Q4	cris	Royalty Purchase Agreement Liability Carrying Value RoyaltyPurchaseAgreementLiabilityCarryingValue	62477000	USD
CY2016Q3	cris	Collaboration Agreement Numberof Programs Licensed CollaborationAgreementNumberofProgramsLicensed	4	program
	cris	Collaboration Agreement Numberof Programs Licensed CollaborationAgreementNumberofProgramsLicensed	4	program
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	101250000	shares
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	151875000	shares
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	67500000	shares
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	101250000	shares
	cris	Share Based Compensation Plans ShareBasedCompensationPlans	2	plan
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6158026	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.43
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M29D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3368150	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.27
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	15156	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.17
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	382124	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.79
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9128896	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.66
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y2M4D
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	83000	USD
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3521493	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.58
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y1M20D
CY2020Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	15000	USD
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	8197121	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	2.81
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y1M6D
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	71000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.75
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.83
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.4
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	1.7
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	2.3
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	2.6
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.81
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.79
CY2020Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	3500000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y4M20D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	624000	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	684000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1833000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1966000	USD

Files In Submission

Name	View Source	Status
0001108205-20-000016-index-headers.html	Edgar Link	pending
0001108205-20-000016-index.html	Edgar Link	pending
0001108205-20-000016.txt	Edgar Link	pending
0001108205-20-000016-xbrl.zip	Edgar Link	pending
cris-20200930.htm	Edgar Link	pending
cris-20200930.xsd	Edgar Link	pending
cris-20200930_cal.xml	Edgar Link	unprocessable
cris-20200930_def.xml	Edgar Link	unprocessable
cris-20200930_htm.xml	Edgar Link	completed
cris-20200930_lab.xml	Edgar Link	unprocessable
cris-20200930_pre.xml	Edgar Link	unprocessable
cris-9302020x10qexx311.htm	Edgar Link	pending
cris-9302020x10qexx312.htm	Edgar Link	pending
cris-9302020x10qexx321.htm	Edgar Link	pending
cris-9302020x10qexx322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRIS
CURIS INC Stock $cris

2020 Q4 Form 10-Q Financial Statement

#000110820520000016 Filed on November 10, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRIS CURIS INC Stock $cris

2020 Q4 Form 10-Q Financial Statement

#000110820520000016 Filed on November 10, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRIS
CURIS INC Stock $cris